Nxera Pharma Forecasts JPY48,800M Revenue and JPY22,800M Core Operating Profit

What happened

Nxera Pharma forecast FY2026 revenue of JPY48,800M, core operating profit of JPY22,800M and operating profit of JPY15,700M. The outlook assumes a US$100M AbbVie upfront payment is recorded in the fourth quarter, conditional on the deal completing by year-end and auditors agreeing with the accounting treatment.

Confirmed

Global impact / market context

The forecast links part of Nxera’s expected revenue and core operating profit to a single licensing payment, rather than only to ongoing sales. If the transaction is delayed or its accounting treatment is not agreed, the expected fourth-quarter contribution may not be recorded as planned.

Analyst inference

The article describes a revised outlook with point estimates, but gives no earlier forecast values or evidence of investor reaction. The key distinction is that the figures are forecasts, not completed results, and depend on deal completion, antitrust clearance and auditor agreement.

Confirmed

What to watch

1. Whether the AbbVie transaction completes by year-end, because Nxera’s forecast assumes the US$100M upfront payment is recorded in the fourth quarter. Confirmed
2. Whether required antitrust clearance and auditor agreement on accounting treatment are obtained, since both are stated conditions for the forecast’s expected payment recognition. Confirmed
3. Any later update to the outlook could clarify how much revenue and core operating profit depend on the licensing payment versus other business activity. Analyst inference

Evidence

• globenewswire.com